Read Your Call Is Important To Us Online
Authors: Laura Penny
Let’s start with the horrid ones. I have been witness to anti-drug rhetoric for the whole of my short life and vividly remember Nancy’s “Just Say No” campaign, and the egg that was your brain frying in the pan that was drugs, and the update in which the girl wrecked her kitchen with the frying pan. That last ad at least acknowledged that drug use will mess up your kitchen—which is demonstrably true. A bout of the munchies can result in sticky surfaces and scattered snack debris, and you can never get all the hot-knife residue off the family silver. Kidding aside, the jackboot-heavy message of each year’s new anti-drug ads is that drugs will kill you, and other people, too. So don’t do any, ever, kids.
The most recent cycle of anti-drug ads I recall were particularly bullshitty. One features two young dudes hanging around a basement, smoking pot and playing with a gun. One of the boys shoots himself in the head. The joint is supposed to be the bad guy in this ad, but, as many people have pointed out, it works way better as an ad for gun control. There was also a series of ads that linked marijuana to Osama with a rinky-dink, child-narrated “This-is-the-house-that-Jack-built” chain of causation. While some warlords have done a brisk trade in heroin, most marijuana—it being a stinky, heavy thing—comes from locales far closer to home than the Middle East, such as Mexico, Canada, and the decommissioned family farms of Red America.
Such ads are, of course, only salvos in a larger battle I choose to call the War on Some Drugs, an unjust war if ever there was one. During George W. Bush’s first term in office, that loon Ashcroft used anti-terrorism laws to collar drug offenders, including Tommy Chong, maker of fine glass pipes. When Tommy Chong, formerly of Cheech and Chong, is getting busted for possession of designer bongcraft, you know that U.S. prosecutions have gotten out of hand. As I’m sure you are aware, prohibition is a price support for black-market cartels and the cause of most drug-related violence. It didn’t work with alcohol during Prohibition, and it certainly is not working now. We could save a lot of money on law enforcement and incarceration by treating addiction medically, rather than legally. Hell, we could even make tax dollars from the legalization of the soft Some Drugs, which would be entirely in keeping with the government’s role as a purveyor of such ruinous vices as gambling, tobacco, and booze. And you certainly don’t need me to tell you that most of the ostensibly bad drugs are more venerable and time-tested than those newfangled Big Pharma drugs that sometimes turn out to have cataclysmic side effects.
There are two main things, beyond the expense and trampling of civil liberties, about the War on Some Drugs that bother me. First, that anti-drug crusaders tend to be hopped up on pills, liquor, God, or their own righteous zeal. My favorite example of this is the infamous 1970 photo of Nixon and Elvis, after the pill-popping president made the pill-gobbling rock god an unofficial deputy in the War on Some Drugs. Second, the War on Some Drugs is largely a war on the poor. The cartels have lawyers and bodyguards and havens to protect themselves from justice. The minor players and users do not. Some drugs are classier than others, but the abjectness of the drug user’s condition, and the force of prohibition against them, is dependent on the class of the user, not on the effects of the substance itself. Woe betide the collared crackhead from Any Ghetto, who can look forward to a stint in prison. Would that he, like Noelle Bush or Rush Limbaugh, had the resources for revolving-door rehab.
I have tried several of the Some Drugs, the operative word being
tried.
I drew my line in the sand at hard drugs like crack and H, but I have certainly inhaled—and popped, guzzled, snorted, and swallowed. My life didn’t go straight to hell, and I encountered most of these substances, controlled and uncontrolled, in stolid middle-class surroundings. I didn’t care much for most of them, but was glad that I had given them a whirl and seen what all the fuss was about. I was never arrested or assaulted or violently ill or driven spontaneously mad. The only drug that has ever made me feel truly wretched is alcohol, the universal solvent of North American good times. I suspect this reflects the drug experience of the vast majority—try a smidge of this and that at a party—but it’s the recovering celebs, shattered junkies, brain-dead Phish followers, and ladies who drive home with a body stuck on the front of their cars that you hear about when you hear about drug use. Nobody gives you an honest warning, like that coke may make you an asshole, or that E may cause you to hug total strangers and dance to lousy music.
The only illegal drug I liked, and continue to like, is pot. We have been on the verge of decriminalizing small amounts of marijuana for personal use up here in Soviet Canuckistan for the past couple of years, but have yet to do so. Canada did pass a medical marijuana law in 2001, and set up a contract with a company called Prairie Plant Systems to establish a pot farm in Flin Flon, Manitoba, to provide marijuana for patients who meet the stringent guidelines, and to provide pot for medical research. The January 2005 stats from the Office of Cannabis Medical Access, the agency that administers the program, show that about eight hundred patients are legally allowed to smoke pot, and five hundred patients are allowed to grow a little for their personal use. Critics of the program argue that there isn’t sufficient scientific evidence that medical marijuana works. This canard has also been used by U.S. federal drug warriors when meddling with Compassion Clubs in the states that allow medical use of marijuana. While smoking anything does damage the lungs, people have turned to the kind bud for thousands of years to soothe pain, aid sleep, and stimulate the appetite. You cannot overdose on it, unlike many pharmaceuticals. As far as I’m concerned, if it’s good enough for Queen Victoria’s cramps, then it’s fine for you and me, too. It’s all well and good to want to keep pot away from the wee developing spuds, but you have to be a merciless puritan to insist we should deny the anodyne charms of a benign weed to the palsied, the cancerous, the seizing, and the wasting away.
Of course, it’s not just the puritans who are keeping the ganja down. Big Pharma is also a player. The Partnership for a Drug-Free America, the nonprofit organization that produced some of the anti-drug ads I referred to earlier, is the beneficiary of hundreds of thousands of dollars in donations from tobacco companies, alcohol companies, and the most generous donors of all, pharmaceutical companies. Drug companies contribute about half the money that goes into making Partnership for a Drug-Free America ads. Big Pharma is happy to whip up a batch of Marinol, its own saleable form of THC, but they don’t want you frying your sweet little egg of a brain with that amateur shit from the street. They want you to take the good drugs—the patented, prescribed fruits of Big Pharma.
Perhaps the only thing as distasteful as the drugs-are-bad ads are the obliviously chirpy drugs-are-good ones. In keeping with the general ad creep, ads for drugs have increased and spread into more media. Such up-with-pharma ads are a recent innovation. In 1997, the Federal Trade Commission decided to allow more direct-to-consumer (DTC) advertising of prescription drugs, and pharmaceutical companies now spend more than $2.7 billion a year shilling their pills. The only Western nations that permit such advertising are New Zealand and the United States. The Canadian government is trying to decide whether or not to allow DTC ads, but this is an utterly moot point, given that most Canadians watch oodles of American television, and I have seen “ask your doctor” ads run on Canadian television for months without any Health Canada crackdown.
I’ll return to the topic of DTC advertising, but first, it is important to note just how big Big Pharma is. Tech, schmech—the savvy investor has known for many moons that pharmaceuticals are the solid bets. A friend of mine made sweet returns on his modest investments throughout the bubble’s bust, when everyone else’s portfolios were tanking. I never saw him read the financial section. He preferred Baudelaire and haiku. When I asked him what his secret was, he summed it up succinctly: drugs. Ah yes, grasshopper, drugs, the answer to so many questions. Pitted skin? Bad mood? Going bald? Getting limp? Nothing that a little Accutane, Paxil, Rogaine, and Viagra can’t fix.
Those are just the lifestyle pills you’ll see on television and in magazines. The Valley of the Dolls stretches far deeper and wider than that. There are all the disease-specific pills: the heart and cholesterol pills people pop to fend off the nation’s number one killer, cardiovascular disease; and the AIDS cocktails, and varying hellacious regimes of cancer drugs. Then there’s the galaxy of painkillers and sleep-inducing elixirs, and all the psychiatric drugs that have yet to achieve the marquee status of Prozac. Then there is the gastrointestinal superstar, Prilosec, an acid-reflux remedy that has spawned a spin-off for the related pain of esophageal erosions, Nexium. And let us not forget the arthritis blockbusters like Celebrex and its recalled fellow, Vioxx, which brings me to another vast pharmaceutical category: drugs for the ravages of old age. While other cultures venerate their elders and treat them as sages, we excel at keeping our old fogies stoned. Chances are, the most pixilated pill-poppin’ rave kid is strung out on only half as many chemicals as your average golden-ager. The majority—more than 80 percent—of seniors take prescription drugs. They also take more prescription drugs than younger people. Over 40 percent report using more than three prescription drugs.
The downside of all of these miraculous pills are that they don’t come cheap. Health care costs have ballooned all over the industrialized world, and pharmaceutical costs are part of that massive swelling. The United States, the globe’s leader in health expenditures, spent about 15 percent of its GDP on health care in 2002, according to the Organization for Economic Cooperation and Development (OECD). In dollars, that’s over $1 trillion, more than double what it was in 1985. Part of this can be blamed on inflation, but a larger share is due to expensive new technologies, the growing needs of an aging population, and the increased price and usage of prescription drugs. The 2004 OECD report notes that costs for prescription drugs grew twice as fast as other health care costs, driving up the overall total.
The Kaiser Foundation did a breakdown of the three factors driving rising drug spending from 1997 to 2002, finding that 42 percent of the increase was due to more drug sales. This is a trend that has been going on for a long time. From 1980 to 2002, prescription drug use tripled. Newer, more expensive brand-name drugs replacing older, more inexpensive ones accounted for another 34 percent of the increase. Price hikes accounted for the other 25 percent. This trinity of increased sales, spiffy new products, and higher prices may be tough on Grandma, but it is fantastic for pharmaceutical companies. From 1995 to 2002, Big Pharma was by far the most profitable sector listed in the Fortune 500. In 2003, they slid to third, behind oil and banking, who had blockbuster years. But big Big Pharma profits are another long trend. The prescription drug industry has enjoyed profit margins two and three times as hefty as those of other industries over the past twenty years. To give you some sense of the gap between Big Pharma and other sectors, consider this: In 2002, which wasn’t even the best year of their reign, Big Pharma’s profits exceeded the total profits of the other 490 companies on the Fortune 500.
In the early nineties, the industry began to face criticism for the rising cost of drugs from managed care organizations eager to cut their own costs. Big Pharma also has to reckon with a tenacious Gray Power lobby that has all the time in the world to circulate petitions, write angry letters, and call in to talk radio. You can’t find a more tear-jerking photograph than a gaggle of frail seniors taking a bus to Canada to fill their prescriptions. It packs a PR wallop. Those poor dear little grannies shouldn’t be on that bus! If seniors are on a bus en masse, they should be en route to a leaf tour or to hear Wayne Newton playing Branson, enjoying some golden-years leisure, not scrimping on scrips.
The standard Big Pharma argument against charges of profiteering is that scientific research requires big bucks. Those selective serotonin reuptake inhibitors (SSRIs) aren’t made of pixie dust and moonbeams; it takes years of hard work by millions of geeks in white coats, tormenting countless small mammals, peering into microscopes, and penning lengthy studies to find a new drug. According to the nice people at the Pharmaceutical Researchers and Manufacturers of America, it can cost up to $500 million to bring a drug to market, and only a fraction of all drugs developed ever make it. Another industry figure claims it costs $800 million to create a new drug. Whenever hated topics like price controls and patent monopolies come up, Big Pharma pleads science and implies that less money or shorter patents means less science means fewer miracle cures. We need to pay for our research, they say, and protect that research from competitors who might spirit the miraculous new chemicals away.
Here’s the rub: Big Pharma doesn’t pick up the tab for all the research that creates the miraculous new chemicals. In fact, when you break it down, research money flows from a variety of sources. Much of it is conducted at public facilities that use taxpayer dollars, courtesy of the National Institutes of Health (NIH). Then there are the ones that come from universities. Then there are chemicals developed in other countries that get patented and introduced in the U.S., like Celexa, a leading SSRI originally developed by the Danish firm H. Lundbeck. A report by Ralph Nader’s advocacy group, Public Citizen, contends that fully 85 percent of the research and development behind the top five drugs of 1995 actually came from taxpayer-funded studies or foreign research.
Tamoxifen, the breast cancer drug, is a nice example. It began as a British birth control pill in the sixties. The Brits tested it as a breast cancer treatment throughout the seventies and eighties. Money from the American taxpayer funded tons and tons of studies and tests in the nineties, and continues to fund research to this day. A billion-dollar concern called AstraZeneca patented it for sale and pays a wee royalty to the NIH while making millions and millions. Tamoxifen is the most widely prescribed breast cancer drug, and they’re testing it as a preventative measure for at-risk women, even though some studies show that it may cause strokes or other cancers. People pay way more for it in the States than in Canada or in Europe, even though it’s the same drug from the same company with plants all over the globe. And when not making cancer drugs—oh, genius of capitalism!—AstraZeneca manufactures pesticides.